Who are Novavax COVID-19 Vaccine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): BNT162b7 Monovalent (OMI BA.4/BA.5), Famtozinameran 5 to 11 Years of age, Moderna mRNA-1273 COVID-19 vaccine, AntiCov-220, Combination BNT162b2 and BNT162b2 OMI, BNT162b2 Bivalent (WT/OMI BA.1).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/novavax-covid-19-vaccine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Novavax COVID-19 Vaccine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Novavax COVID-19 Vaccine (Novavax COVID-19 Vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Protein subunit vaccine. Area: Immunology.

phase 3 Protein subunit vaccine SARS-CoV-2 spike protein Immunology Biologic Live · refreshed every 30 min

Target snapshot

Novavax COVID-19 Vaccine (Novavax COVID-19 Vaccine) — Novavax. Novavax COVID-19 Vaccine uses recombinant spike protein nanoparticles with a saponin-based adjuvant to stimulate immune responses against SARS-CoV-2.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Novavax COVID-19 Vaccine TARGET	Novavax COVID-19 Vaccine	Novavax	phase 3	Protein subunit vaccine	SARS-CoV-2 spike protein
BNT162b7 Monovalent (OMI BA.4/BA.5)	bnt162b7-monovalent-omi-ba-4-ba-5	Pfizer	marketed	vaccine	SARS-CoV-2 spike protein
Famtozinameran 5 to 11 Years of age	famtozinameran-5-to-11-years-of-age	Pfizer	marketed	Monoclonal antibody	SARS-CoV-2 spike protein
Moderna mRNA-1273 COVID-19 vaccine	Moderna mRNA-1273 COVID-19 vaccine	National Institute of Allergy and Infectious Diseases (NIAID)	marketed	mRNA vaccine	SARS-CoV-2 spike protein (S protein)
AntiCov-220	AntiCov-220	Nguyen Thi Trieu, MD	marketed	Monoclonal antibody	SARS-CoV-2 spike protein
Combination BNT162b2 and BNT162b2 OMI	combination-bnt162b2-and-bnt162b2-omi	Pfizer	marketed	mRNA vaccine	SARS-CoV-2 spike protein
BNT162b2 Bivalent (WT/OMI BA.1)	bnt162b2-bivalent-wt-omi-ba-1	Pfizer	marketed	mRNA vaccine	SARS-CoV-2 spike protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Protein subunit vaccine class)

Novavax · 2 drugs in this class
Taoyuan General Hospital · 2 drugs in this class
Medigen Vaccine Biologics Corp. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Novavax COVID-19 Vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/novavax-covid-19-vaccine. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab